Marketed through Renaissance’s division Prestium Pharma, the products of GSK and Stiefel include Evoclin Foam, Extina Foam, Luxiq Foam, Olux Foam, Olux-E Foam, Vusion Ointment, Zovirax Capsules, Zovirax Tablets, Zovirax Suspension.
Renaissance president and CEO Pierre Fréchette said that the transaction is in-line with its strategy of acquiring niche products that it can both manufacture within its internal network and market through the commercial group.
"The RoundTable team was instrumental in helping to source, diligence and complete such an important acquisition," Fréchette added.
Stiefel president Simon Jose said, "This agreement allows US patients to continue to have access to treatments they value and allows the Stiefel US Team to focus on growth and development of new treatments within our core dermatology portfolio."
Serving in the US and Canada, Renaissance focuses on contract development and manufacturing as well as commercialization of branded and generic prescription products.